Arthur M Deboeck

US Patent:

7858118, Dec 28, 2010

Filed:

Apr 11, 2002

Appl. No.:

10/119939

Inventors:

Arthur M. Deboeck - Gurabo PR, US
Francis Vanderbist - Meise, BE
Antonio Sereno - Melsbroeck, BE

Assignee:

Galephar Pharmaceutical Research, Inc. - Juncos PR

International Classification:

A61K 9/48
A61K 9/20
A61K 9/14

US Classification:

424456, 424451, 424458, 424459, 424464, 424489

Abstract:

An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (T) of greater than 10 hours, and peak Tramadol plasma concentration (C) which are less than three times the plasma concentration obtained 24 hours after administration (C) of a single dose of the composition.

US Patent:

20040247530, Dec 9, 2004

Filed:

Aug 2, 2004

Appl. No.:

10/486217

Inventors:

Arthur Deboeck - Gurabo PR, US
Philippe Baudier - Uccle, BE
Francis Vanderbist - Beersel, BE

International Classification:

A61L009/04
A61K009/14

US Classification:

424/046000, 514/171000, 514/649000, 514/053000

Abstract:

Pharmaceutical composition for inhalation, containing as active ingredient effective amounts of salmeterol or a physiologically salt of salmeterol or a solvate thereof, and budesonide or a therapeutically salt of budesonide or a solvate thereof, wherein the molecular ratio of salmeterol component to budesonide component is in the range 1:2 to 1:50, together with a pharmaceutically acceptable carrier.

US Patent:

20050032878, Feb 10, 2005

Filed:

Aug 7, 2002

Appl. No.:

10/486219

Inventors:

Arthur Deboeck - Gurabo PR, US
Francis Vanderbist - Beersel, BE
Philippe Baudier - Uccle, BE
Antonio Sereno - Melsbroek, BE

International Classification:

A61K031/401
A61K031/366
A61K031/192
A61K031/225

US Classification:

514423000, 514460000, 514548000, 514571000, 424452000

Abstract:

Oral pharmaceutical composition containing, in the same pharmaceutical form, effective amounts of a HMG-CoA reductase inhibitor derivative and of a PPARa, especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissolution and/or bioavailability of the drugs from the said composition.

US Patent:

20050154060, Jul 14, 2005

Filed:

Dec 13, 2004

Appl. No.:

11/009017

Inventors:

Arthur Deboeck - Gurabo PR, US
Francis Vanderbist - Waterloo, BE
Phillippe Baudier - Waterloo, BE

Assignee:

Galephar Pharmaceutical Research, Inc. - Juncos PR

International Classification:

A61K031/198

US Classification:

514562000

Abstract:

The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following inflammatory markers IL_6 and IL_8 and/or the increase in the lungs and/or the nasal cavity of the anti-inflammatory markers IL_10. The present invention also discloses pharmaceutical compositions for pulmonary and/or nasal administration of basic amino salts of acetylcysteine characterised that they have anti-inflammatory properties and may be useful to treat inflammatory lung and/or nasal conditions found in illnesses such as COPD, asthma, cystic fibrosis and the like.

US Patent:

20060254583, Nov 16, 2006

Filed:

Mar 17, 2004

Appl. No.:

10/549124

Inventors:

Arthur Deboeck - Gurabo PR, US
Philippe Bauduer - Uccle, BE

International Classification:

A61M 15/00
A61M 16/10

US Classification:

128203150, 128203120, 128203210

Abstract:

An improved dry powder inhalation system comprising: at least one micronized active ingredient in an hydroxypropylmethylcellulose capsule (), and an dry powder inhaler device equipped with piercing systems () having an equivalent diameter of not less than 0.8 mm.

US Patent:

20070071689, Mar 29, 2007

Filed:

Aug 6, 2003

Appl. No.:

10/567408

Inventors:

Arthur Deboeck - Gurabo PR, US
Philippe Baudier - Uccle, BE
Francis Vanderbist - Beersel, BE

Assignee:

GALEPHAR M/F - Marche-en-Famenne

International Classification:

A61K 38/04
A61K 31/4745
A61K 31/137

US Classification:

424046000, 514019000, 514649000, 514291000

Abstract:

pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.

US Patent:

20070092567, Apr 26, 2007

Filed:

Feb 6, 2006

Appl. No.:

11/347822

Inventors:

Arthur Deboeck - Gurabo PR, US
Philippe Baudier - Uccle, BE
Francis Vanderbist - Beersel, BE
Antonio Sereno - Melsbroeck, BE

Assignee:

GALEPHAR M/F - Marche-en-Famenne

International Classification:

A61K 31/714
A61K 31/525
A61K 31/51
A61K 31/366
A61K 31/22
A61K 31/192
A61K 9/22

US Classification:

424468000, 514251000, 514052000, 514276000, 514350000, 514460000, 514548000, 514571000

Abstract:

A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (T) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.

US Patent:

20070122478, May 31, 2007

Filed:

Nov 16, 2006

Appl. No.:

11/600201

Inventors:

Arthur Deboeck - Gurabo PR, US
Francis Vanderbist - Melse, BE
Antonio Sereno - Melsbroeck, BE

International Classification:

A61K 31/137
A61K 9/22

US Classification:

424468000, 514650000

Abstract:

The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appears within the first hours after administration, the time to maximal Tramadol content Tis at least 10 hours and the peak Tramadol concentration is less than three times the concentration obtained after 24 hours of said administration.